Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2684-2692

  Innominato, Pasquale F ^a,b   Giacchetti, Sylvie ^a,b   Bjarnason, Georg A ^c   Focan, Christian ^d   Garufi, Carlo ^e   Coudert, Bruno ^f   Iacobelli, Stefano ^g,h   Tampellini, Marco ⁱ   Durando, Xavier ^j   Mormont, Marie Christine ^a   Waterhouse, Jim ^k   Lévi, Francis A ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d Clinique Saint Joseph   (Belgium)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g UNIVERSITY OF CHIETI   (Italy)

^h University G d'Annunzio Medical School ^*  (Italy)

ⁱ SAN LUIGI GONZAGA HOSPITAL   (Italy)

^j CENTRE JEAN PERRIN   (France)

^k LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

more..

Author keywords

actimetry; chronotherapy; circadian; colorectal cancer; rest activity rhythm

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACTIMETRY; ADULT; AGED; ANEMIA; ARTICLE; BED; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONOTHERAPY; CIRCADIAN RHYTHM; COLORECTAL CANCER; DIARRHEA; DISEASE ASSOCIATION; FATIGUE; FEMALE; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; IN BED VERSUS OUT OF BED; LEUKOPENIA; LOCOMOTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL PREDICTION; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CIRCADIAN RHYTHM; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; REST; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84867087511     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27574     Document Type: Article

References (50)

1. Bosetti C, Levi F, Rosato V, et al. Recent trends in colorectal cancer mortality in Europe. Int J Cancer 2011; 129: 180-91.
2. Eng C,. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 2009; 6: 207-18.
3. Innominato PF, Mormont MC, Rich TA, et al. Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. Integr Cancer Ther 2009; 8: 361-70.
4. Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005; 23: 8500-11.
5. Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100: 1155-66.
6. Miller AH, Ancoli-Israel S, Bower JE, et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008; 26: 971-82.
7. Seruga B, Zhang H, Bernstein LJ, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8: 887-99.
8. Reyes-Gibby CC, Wu X, Spitz M, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 2008; 9: 777-85.
9. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
10. Sephton S, Spiegel D,. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 2003; 17: 321-8.
11. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 1757-64.
12. Schibler U,. Control of circadian gene expression and physiology by central and peripheral clocks. Annu Rev Physiol 2010; 72.
13. Innominato PF, Levi FA, Bjarnason GA,. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 2010; 62: 979-1001.
14. Levi F, Okyar A, Dulong S, et al. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010; 50: 377-421.
15. Fu L, Pelicano H, Liu J, et al. The circadian gene period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002; 111: 41-50.
16. Filipski E, Innominato PF, Wu M, et al. Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst 2005; 97: 507-17.
17. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002; 94: 690-7.
18. Li XM, Delaunay F, Dulong S, et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res 2010; 70: 3351-60.
19. Berger AM, Wielgus KK, Young-McCaughan S, et al. Methodological challenges when using actigraphy in research. J Pain Symptom Manage 2008; 36: 191-9.
20. Ancoli-Israel S, Cole R, Alessi C, et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 2003; 26: 342-92.
21. Ortiz-Tudela E, Martinez-Nicolas A, Campos M, et al. A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol 2010; 6: e1000996.
22. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000; 6: 3038-45.
23. Levi F, Parganiha A, Karaboué A, et al. Circadian robustness, an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2012; 30:abstract # 464 ]. 2012 Gastrointestinal Cancers Symposium, ASCO.
24. Innominato PF, Focan C, Gorlia T, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 2009; 69: 4700-7.
25. Mormont MC, Waterhouse J,. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol Int 2002; 19: 313-23.
26. Fouladiun M, Korner U, Gunnebo L, et al. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 2007; 13: 6379-85.
27. Berger AM, Wielgus K, Hertzog M, et al. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer 2010; 18: 105-14.
28. Roscoe JA, Morrow GR, Hickok JT, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer 2002; 10: 329-36.
29. Ahowesso C, Li XM, Zampera S, et al. Sex and dosing-time dependencies in irinotecan-induced circadian disruption. Chronobiol Int 2011; 28: 458-70.
30. Li XM, Vincenti M, Levi F,. Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol Int 2002; 19: 43-55.
31. Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24: 3562-9.
32. Savard J, Liu L, Natarajan L, et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep 2009; 32: 1155-60.
33. Ortiz-Tudela E, Innominato PF, Iurisci I, et al. Chemotherapy-induced circadian disruption in cancer patients. XII Congress of the European Biological Rhythms Society Oxford, UK, August 20-26, 2011.
34. Minors D, Akerstedt T, Atkinson G, et al. The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. Chronobiol Int 1996; 13: 27-34.
35. Iop A, Manfredi AM, Bonura S,. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 2004; 15: 712-20.
36. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-95.
37. Berger AM, Grem JL, Visovsky C, et al. Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum 2010; 37: E359-E369.
38. Iurisci I, Rich T, Levi F, et al. Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer. J Clin Oncol 2007; 25: e17-e19.
39. Lévi F, Schibler U,. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007; 47: 593-628.
40. Cain SW, Dennison CF, Zeitzer JM, et al. Sex differences in phase angle of entrainment and melatonin amplitude in humans. J Biol Rhythms 2010; 25: 288-96.
41. Roenneberg T, Merrow M,. Entrainment of the human circadian clock. Cold Spring Harb Symp Quant Biol 2007; 72: 293-9.
42. Duffy JF, Cain SW, Chang AM, et al. Sex difference in the near-24-hour intrinsic period of the human circadian timing system. Proc Natl Acad Sci USA 2011; 108 (Suppl 3): 15602-8.
43. Levi F, Focan C, Karaboue A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 2007; 59: 1015-35.
44. Foster RG, Wulff K,. The rhythm of rest and excess. Nat Rev Neurosci 2005; 6: 407-14.
45. Waterhouse J, Reilly T, Atkinson G, et al. Jet lag: trends and coping strategies. Lancet 2007; 369: 1117-29.
46. Walsh D, Rybicki L,. Symptom clustering in advanced cancer. Support Care Cancer 2006; 14: 831-6.
47. Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34: 94-104.
48. Aprile G, Ramoni M, Keefe D, et al. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 2008; 112: 284-92.
49. Cheung WY, Le LW, Zimmermann C,. Symptom clusters in patients with advanced cancers. Support Care Cancer 2009; 17: 1223-30.
50. Hrushesky WJ, Grutsch JF, Wood P, et al. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther 2009; 8: 387-97.